ArticleClinical Medicine Insights. Oncology2010

Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy.

Mariana Serpa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.